menu
    • menu
    [{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Rampart Pharma Announces Patient Enrollment and Dosing Underway in Phase 1 Study Evaluating Novel Non-Opioid Approach to Pain with Lead Program, SRP-3D (DA)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Acetaminophen Analog","moa":"COX","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"South Rampart Pharma \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ Quotient Sciences"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Rampart Pharma Announces Late-Breaking Presentation at IASP 2022 World Congress on Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Diethylamide","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"South Rampart Pharma \/ NIH","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ NIH"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Rampart Pharma Issued Composition of Matter Patent for Novel Non-Toxic Treatment for Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Acetaminophen Analog","moa":"COX","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"South Rampart Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ Not Applicable"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Rampart Pharma Announces Presentation at Arrowhead's 16th Annual Pain Therapeutics Summit","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Diethylamide","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"South Rampart Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ Not Applicable"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Rampart Pharma Announces First Patient Enrolled in Multiple Ascending Dose Portion of Ongoing Phase 1 Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Diethylamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"South Rampart Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ Not Applicable"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"National Institute of Health","pharmaFlowCategory":"D","amount":"$1.9 million","upfrontCash":"Undisclosed","newsHeadline":"South Rampart Pharma Awarded Second NIH Grant for Commercialization Readiness Pilot Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Funding","leadProduct":"Diethylamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"South Rampart Pharma \/ National Institute of Health","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ National Institute of Health"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Rampart Pharma Receives U.S. FDA Fast Track Designation for SRP-001 for Acute Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Diethylamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"South Rampart Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ Not Applicable"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Rampart Pharma Successfully Completes Phase 1 Study and Expands Phase 2 Plans to Include Neuropathic and Acute Pain Trials","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Diethylamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"South Rampart Pharma \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ Quotient Sciences"}]

    Find Clinical Drug Pipeline Developments & Deals by South Rampart Pharma

    Menu

    South Rampart Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            South Rampart Pharma

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            South Rampart Pharma

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diethylamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Quotient Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            South Rampart Pharma Successfully Completes Phase 1 Study and Expands Phase 2 Plans to Include Neuropathic and...

                            Details : SRP 3D (diethylamide) is a novel, first-in-class non-opioid analgesic that activates pain signaling pathways in the midbrain's periaqueductal grey (PAG) region without liver and kidney toxicities. It is being evaluated in phase 1 clinical trials for the ...

                            Brand Name : SRP 3D

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 02, 2024

                            Lead Product(s) : Diethylamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Quotient Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            South Rampart Pharma

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            South Rampart Pharma

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diethylamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            South Rampart Pharma Receives U.S. FDA Fast Track Designation for SRP-001 for Acute Pain

                            Details : SRP-001 is a novel, first-in-class non-opioid analgesic that activates pain signaling pathways in the midbrain's periaqueductal grey (PAG) region without liver and kidney toxicities and is being developed for the treatment of acute pain.

                            Brand Name : SRP-001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 12, 2023

                            Lead Product(s) : Diethylamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            South Rampart Pharma

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            South Rampart Pharma

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diethylamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : National Institute of Health

                            Deal Size : $1.9 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            South Rampart Pharma Awarded Second NIH Grant for Commercialization Readiness Pilot Program

                            Details : The funding Validates the Business Case and Commercial Opportunity of SRP-001 (diethylamide), a first-in-class, novel, non-opioid small molecule analgesic for Acute and Chronic Pain.

                            Brand Name : SRP-001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 21, 2023

                            Lead Product(s) : Diethylamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : National Institute of Health

                            Deal Size : $1.9 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            South Rampart Pharma

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            South Rampart Pharma

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diethylamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            South Rampart Pharma Announces First Patient Enrolled in Multiple Ascending Dose Portion of Ongoing Phase 1 Cl...

                            Details : SRP-001 (diethylamide) is a novel, non-opioid investigational drug that avoids the liver toxicity associated with acetaminophen, positioned to address the unmet medical need for non-toxic and non-addictive acute and chronic pain therapeutics.

                            Brand Name : SRP-001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 22, 2023

                            Lead Product(s) : Diethylamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            South Rampart Pharma

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            South Rampart Pharma

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diethylamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            South Rampart Pharma Announces Presentation at Arrowhead's 16th Annual Pain Therapeutics Summit

                            Details : SRP-001 is an AM404 agonist that targets the endocannabinoid (CB1) pain receptors in the brain,for the treatment of acute and chronic pain,is currently being investigated in a two-part, double-blind, placebo-controlled Phase 1 study.

                            Brand Name : SRP-001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 21, 2022

                            Lead Product(s) : Diethylamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            South Rampart Pharma

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            South Rampart Pharma

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acetaminophen Analog

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            South Rampart Pharma Issued Composition of Matter Patent for Novel Non-Toxic Treatment for Pain

                            Details : SRP-001 (acetaminophen analog) is an AM404 agonist that targets the endocannabinoid (CB1) pain receptors in the brain. In multiple, validated non-clinical studies, SRP-001 demonstrated consistent, superior analgesic activity than that of acetaminophen.

                            Brand Name : SRP-001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 04, 2022

                            Lead Product(s) : Acetaminophen Analog

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            South Rampart Pharma

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            South Rampart Pharma

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diethylamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : National Institutes of Health

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            South Rampart Pharma Announces Late-Breaking Presentation at IASP 2022 World Congress on Pain

                            Details : SRP-001, is novel acetaminophen analog with unique mechanism of action for its lack of liver toxicity present in acetaminophen. In development to treat acute and other forms of pain, demonstrates that SRP-001 offers a compelling safety profile over avail...

                            Brand Name : SRP-001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 25, 2022

                            Lead Product(s) : Diethylamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : National Institutes of Health

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            South Rampart Pharma

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            South Rampart Pharma

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acetaminophen Analog

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Quotient Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            South Rampart Pharma Announces Patient Enrollment and Dosing Underway in Phase 1 Study Evaluating Novel Non-Op...

                            Details : SRP-3D (DA)/SRP-001, (Acetaminophen Analog) has shown promising efficacy in reducing both pain and fever while lacking the liver and kidney toxicity associated with current prescription and over-the-counter analgesics.

                            Brand Name : SRP-3D (DA)

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 23, 2022

                            Lead Product(s) : Acetaminophen Analog

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Quotient Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth